surmount-osa trial tirzepatide results for the Treatment of Obstructive Sleep Apnea and Obesity Tirzepatide Shows Promise in Reducing

This work was supported by Integrated Chinese and Western Medicine (YC-2023-0404), Fudan Zhangjiang Clinical Medicine Innovation Fund Project (KP0202118), Fudan Good Practice Program of Teaching and Learning (FD2023A227), Project of Key Medical Discipline of Pudong Hospital of Fudan University (Zdxk2020-11), Project of Key Medical Specialty and Treatment Center of Pudong Hospital of Fudan University (Zdzk2020-24), Pudong New Area Clinical Plateau Discipline Project (PWYgy-2021-03), the Natural Science Foundation of China (21675034), National Natural Science Foundation of China (81370932), Shanghai Natural Science Foundation (19ZR1447500), Pudong New Area Clinical Characteristic Discipline Project (PWYts2021-11), Pudong New Area Clinical Characteristic Discipline Project (PWYts2021-01), Pudong Research Project (YC-2023-0202, YC-2023-0607, PWRI2023-08), Wenzhou Medical University Education Grant (JG2021197), Pudong Research Project (PWRl2023-08, YC-2023-0128

These include aspects like biology, personal behaviors, access to healthy environments, cultural influences, and differences in quality of health care systems, factors that can affect people throughout their lives (22)

Cardiovascular outcomes : Neither has completed a CVOT, though tirzepatide's SURPASS-CVOT is underway

These adjustments can make it harder to fall asleep or disrupt how a person sleeps

Toward a deeper understanding of gut microbiome in depression: the promise of clinical applicability

The standard titration schedule accommodates this adjustment